Bio Roundup: Opioid Exposé, Gilead’s Gambit, Life Science IPOs & More
Summary
The opioid crisis reaches all corners of the nation, and newly released data this week revealed how the growth of the epidemic tracked with a massive increase in the production and distribution of these drugs. In other news this week, Gilead Sciences (NASDAQ: GILD) made a $5 billion investment, a startup raised a $100 million-plus Series A round, and Wall Street welcomed a few more biotechs. —Gilead Sciences paid Galapagos NV (NASDAQ: GLPG) about $5.1 billion to up its stake in the Belgian biotech and kick off a wide-ranging alliance that will give the Foster City, CA, company rights or options to a slew of experimental drugs for inflammatory diseases. —In a presentation Tuesday night, Tesla and SpaceX founder Elon Musk unveiled the details behind his new startup, Neuralink, which is developing microchips and “information strips” that would be implanted into peoples’ brains to help communicate with machines. —Novartis tried to dispel the notion from recent reports that patients have struggled to get access to its pricey spinal muscular atrophy gene therapy Zolgensma due to restrictive payer policies.
Funding
Review available funding amount, funding date, investors, and linked company information related to Bio Roundup: Opioid Exposé, Gilead’s Gambit, Life Science IPOs & More in the interactive ISVWorld profile.
Classifications
AskAI Classifications
LabelsLinked Companies
